Posted inBiotechnology
AbbVie takes $3.5B hit after emraclidine’s phase 2 flop in schizophrenia
The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma said…
Posted inBiotechnology
Revolutionary Self-Destructing Vaccine Shows Improved Tuberculosis Protection in Monkeys
A novel vaccine strategy utilizing a self-destructing strain of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) has shown promising results in combating…
Posted inBiotechnology
Eli Lilly, Andreessen Horowitz link up on $500M biotech venture fund
Eli Lilly and venture capital firm Andreessen Horowitz (a16z) are joining forces to create a unique new fund dubbed the…
Posted inBiotechnology
Sustainable Building Features Foster Optimal Indoor Climate
A groundbreaking advancement in indoor humidity regulation has emerged from ETH Zurich, where a team of researchers has unveiled a…
Posted inBiotechnology
Study Reveals Brain Differences Associated with Elevated Disordered Eating in Young Individuals
A significant finding has emerged from recent research conducted by the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s…
Posted inBiotechnology
Novo Holdings-backed Windward generates $200M series A, inks $970M biobucks deal for clinical antibody
Windward Bio has landed with a flurry of announcements, circling in a $200 million series A and offering up to $970…
Posted inBiotechnology
Eli Lilly pushes into pulmonary fibrosis with $99M deal for Mediar’s midphase prospect
Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in upfront and…
Posted inBiotechnology
Bausch + Lomb pens $485M-plus biobucks pact with City Tx for RNAi eye disease work
City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder…
Posted inBiotechnology
Pfizer’s PD-1 prospect beats age-old incumbent in phase 3 bladder cancer trial
Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in bladder…
Posted inBiotechnology
Biotech creator and China’s Keymed launch antibody company with $180M series A
U.S.-based biotech builder Mountainfield Venture Partners and China’s Keymed Biosciences have launched a new company armed with $180 million in…